MX2023005203A - Lipid nanoparticles for delivering mrna vaccines. - Google Patents

Lipid nanoparticles for delivering mrna vaccines.

Info

Publication number
MX2023005203A
MX2023005203A MX2023005203A MX2023005203A MX2023005203A MX 2023005203 A MX2023005203 A MX 2023005203A MX 2023005203 A MX2023005203 A MX 2023005203A MX 2023005203 A MX2023005203 A MX 2023005203A MX 2023005203 A MX2023005203 A MX 2023005203A
Authority
MX
Mexico
Prior art keywords
lipid nanoparticles
mrna vaccines
delivering mrna
delivering
mrna
Prior art date
Application number
MX2023005203A
Other languages
Spanish (es)
Inventor
Frank Derosa
Anusha Dias
Shrirang Karve
Asad Khanmohammed
Khang Anh Tran
Danilo Casimiro
Timothy Tibbitts
Sudha Chivukula
Rebecca L Goldman
Hardip Rajeshbhai Gopani
Kirill Kalnin
Priyal Patel
Timothy Plitnik
Ashish L Sarode
Montoya Natalia Vargas
Angela Lynne Beaulieu
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Priority claimed from PCT/US2021/058250 external-priority patent/WO2022099003A1/en
Publication of MX2023005203A publication Critical patent/MX2023005203A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided are novel lipid nanoparticles for delivering nucleic acids such as mRNA. Also provided are methods of making and using lipid nanoparticles for delivering nucleic acids such as mRNA.
MX2023005203A 2020-11-06 2021-11-05 Lipid nanoparticles for delivering mrna vaccines. MX2023005203A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063110965P 2020-11-06 2020-11-06
US202163212523P 2021-06-18 2021-06-18
EP21315198 2021-10-13
PCT/US2021/058250 WO2022099003A1 (en) 2020-11-06 2021-11-05 Lipid nanoparticles for delivering mrna vaccines

Publications (1)

Publication Number Publication Date
MX2023005203A true MX2023005203A (en) 2023-07-13

Family

ID=86184333

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005203A MX2023005203A (en) 2020-11-06 2021-11-05 Lipid nanoparticles for delivering mrna vaccines.

Country Status (9)

Country Link
EP (1) EP4240335A1 (en)
JP (1) JP2023550600A (en)
KR (1) KR20230104223A (en)
CN (1) CN116406299A (en)
AU (1) AU2021374976A1 (en)
CA (1) CA3194325A1 (en)
CO (1) CO2023005218A2 (en)
IL (1) IL302631A (en)
MX (1) MX2023005203A (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024097874A1 (en) * 2022-11-03 2024-05-10 Modernatx, Inc. Chemical stability of mrna
CN118021957A (en) * 2022-11-11 2024-05-14 深圳先进技术研究院 MRNA for encoding anti-avian influenza H7N9 virus antibody and preparation method and application thereof
CN118021956A (en) * 2022-11-11 2024-05-14 深圳先进技术研究院 MRNA for encoding anti-avian influenza H7N9 virus antibody and preparation method and application thereof

Also Published As

Publication number Publication date
KR20230104223A (en) 2023-07-07
EP4240335A1 (en) 2023-09-13
IL302631A (en) 2023-07-01
CN116406299A (en) 2023-07-07
CA3194325A1 (en) 2022-05-12
AU2021374976A1 (en) 2023-06-29
JP2023550600A (en) 2023-12-04
CO2023005218A2 (en) 2023-05-19

Similar Documents

Publication Publication Date Title
MX2023005203A (en) Lipid nanoparticles for delivering mrna vaccines.
MX2022007680A (en) Lipid nanoparticles for delivery of nucleic acids.
GB2600859B (en) Improved lipid nanoparticles for delivery of nucleic acids
GB2589795B (en) Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
PH12020552100A1 (en) Modified guide rnas for gene editing
EP3846822A4 (en) Compositions and methods for organ specific delivery of nucleic acids
PH12018500965A1 (en) Methods and compositions for gene editing in hematopoietic stem cells
AU2017279565B2 (en) RNA formulation for immunotherapy
EP3846857A4 (en) Compositions and methods for organ specific delivery of nucleic acids
EP4219532A3 (en) Compositions and methods for transient gene therapy with enhanced stability
MX2021005389A (en) Lipid nanoparticle formulations.
WO2022155530A8 (en) Variant strain-based coronavirus vaccines
MX2018016389A (en) Compositions and methods for delivering messenger rna.
PH12017501501A1 (en) Compositions and methods for inhibiting expression of tmprss6 gene
EP4286012A3 (en) Compounds and compositions for intracellular delivery of therapeutic agents
MX2023006604A (en) Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof.
GB2538683A8 (en) Irinotecan hydrochloride composite phospholipid composition preparation method and use thereof
PH12014502870A1 (en) Method of producing recombinant iduronate-2-sulfatase
AU2017260426A1 (en) Engineered nucleases useful for treatment of hemophilia A
MX336787B (en) Genetically engineered microorganisms comprising 4-hydroxybenzoly-coa thioesterases and methods of using the same for producing free fatty acids and fatty acid derivatives.
MX2021014465A (en) Rnai constructs for inhibiting scap expression and methods of use thereof.
IL309505A (en) Novel lipid nanoparticles for delivery of nucleic acids
MX2023000511A (en) Lipid nanoparticles for delivering therapeutics to lungs.
WO2019036043A3 (en) A method to generate a cocktail of personalized cancer vaccines from tumor-derived genetic alterations for the treatment of cancer
MX2021012813A (en) Slow-release cytokine conjugates.